Highlight selection of radiochemistry and radiopharmacy developments by editorial board
-
Published:2022-04-26
Issue:1
Volume:7
Page:
-
ISSN:2365-421X
-
Container-title:EJNMMI Radiopharmacy and Chemistry
-
language:en
-
Short-container-title:EJNMMI radiopharm. chem.
Author:
Bernardes Emerson, Caravan Peter, van Dam R. Michael, Deuther-Conrad WinnieORCID, Ellis Beverley, Furumoto Shozo, Guillet Benjamin, Huang Ya-Yao, Jia Hongmei, Laverman Peter, Li Zijing, Liu Zhaofei, Lodi Filippo, Miao Yubin, Perk Lars, Schirrmacher Ralf, Vercoullie Johnny, Yang Hua, Yang Min, Yang Xing, Zhang Junbo, Zhang Ming-Rong, Zhu Hua
Abstract
Abstract
Background
The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development.
Results
This commentary of highlights has resulted in 23 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals and also a contribution in relation to MRI-agents is included.
Conclusion
Trends in (radio)chemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry.
Funder
Helmholtz-Zentrum Dresden - Rossendorf e. V.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Radiology, Nuclear Medicine and imaging,Analytical Chemistry
Reference47 articles.
1. Abou DS, Thiele NA, Gutsche NT, Villmer A, Zhang H, Woods JJ, Baidoo KE, Escorcia FE, Wilson JJ, Thorek DLJ. Towards the stable chelation of radium for biomedical applications with an 18-membered macrocyclic ligand. Chem Sci. 2021;12:3733–42. 2. Archibald SJ, Allot L. The aluminium 18F fluorine revolution: simple radiochemistry with a big impact for radiolabelled biomolecules. EJNMMI Radiopharm Chem. 2021;6:30. 3. Chen M, Chen Z, Castillo JB, Cui L, Zhou K, Shen B, Xie J, Chin FT, Rao J. [18F]-C-SNAT4: an improved caspase-3-sensitive nanoaggregation PET tracer for imaging of tumor responses to chemo- and immunotherapies. EJNMMI. 2021a;48:3386–99. 4. Chen H, Zhao L, Ruan D, Pang Y, Hao B, Dai Y, et al. Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings. EJNMMI. 2021b;48:73–86. 5. Cisternino S, Cazzola E, Skliarova H, Amico J, Malachini M, Gorgoni G, Anselmi-Tamburini U, Esposito J. Target manufacturing by Spark Plasma Sintering for efficient 89Zr production. Nucl Med Biol. 2022;104–105:38–46.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|